ASP Isotopes Inc. discloses material events, capital structure, governance matters, operating results and project risks through its SEC filings. The company’s 8-K reports document business updates tied to isotope enrichment, PET Labs radiopharmaceutical operations, Quantum Leap Energy, research collaborations, advisory-board matters, and Renergen-related helium and LNG project disclosures.
Its filings also include Regulation FD exhibits, amended 8-K risk-factor disclosures, and a Form 12b-25 notice for annual-report timing. Recurring disclosure subjects include ASP and Quantum Enrichment technologies, Pretoria enrichment facilities, nuclear medicine and semiconductor isotope applications, nuclear fuel-cycle initiatives, financial position, forward-looking statements, permitting, development costs, and operational risks at the Virginia Gas Project.
ASP Isotopes Inc. notified the SEC it cannot timely file its Form 10-Q for the period ended March 31, 2026. The company states the delay stems from obtaining and compiling required information and says it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date.
The notification was signed by Heather Kiessling, Chief Financial Officer, on May 15, 2026.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy, announced a non-binding Memorandum of Understanding with a European nuclear technology company to explore a long-term collaboration for advanced nuclear fuel supply.
The MOU covers potential supply of high assay low enriched uranium (HALEU) with uranium-235 content greater than 10%. The parties plan technical and economic assessments, with a framework where the partner could provide uranium feedstock to Quantum Leap Energy’s planned conversion and enrichment facilities, and Quantum Leap Energy could enrich and potentially deconvert it for delivery.
The MOU runs through December 31, 2030, and contemplates non-binding estimates of HALEU quantities, with potential deliveries beginning in 2028 and volumes scaling up through 2036, aligned with the partner’s reactor development timeline and fuel needs.
ASP Isotopes Inc. reported that its wholly owned subsidiary, Quantum Leap Energy LLC (QLE), has appointed Dr. Peter S. Fiske to QLE’s Strategic Advisory Board. QLE focuses on innovative technologies across the nuclear fuel cycle, including uranium enrichment and lithium isotope separation, using proprietary Aerodynamic Separation Process and Quantum Enrichment technologies.
Dr. Fiske previously led the U.S. Department of Energy’s five-year, $110 million National Alliance for Water Innovation hub and has extensive experience in technology commercialization, government partnerships, and advanced materials. The press release also reiterates QLE and ASP Isotopes’ use of forward-looking statements subject to significant technical, regulatory, and funding risks.
ASP Isotopes Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add Part III information on directors, executive officers, compensation, ownership and auditor fees. The amendment does not update financial statements and should be read together with the original filing.
For 2025, CEO Paul Mann received total compensation of about $16.8 million, including salary, cash bonus and significant equity awards. The filing also discloses that non‑affiliate market value was approximately $399.8 million and that 125,903,447 common shares were outstanding as of April 29, 2026.
BlackRock, Inc. files an amended Schedule 13G reporting beneficial ownership of 8,274,763 shares of ASP Isotopes Inc. The amendment (Amendment No. 1) lists 8,274,763 shares beneficially owned, representing 6.6% of the class, with 8,117,277 shares of sole voting power and 8,274,763 shares of sole dispositive power. The cover shows a 03/31/2026 reference and the filing is signed on 04/27/2026. The filing states the holdings reflect aggregated positions of Reporting Business Units of BlackRock and notes various persons may have rights to dividends or proceeds but no other single person holds more than 5%.
ASP Isotopes Inc. COO Robert Ainscow reported an open-market sale of 22,500 shares of Common Stock at a weighted average price of $5.205 per share. According to the disclosure, this was a "sell to cover" transaction under a Rule 10b5-1 trading plan adopted on June 9, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, he directly held 1,490,317 shares, so the transaction represents a small portion of his overall position.
ASP Isotopes Inc. Chief Financial Officer Heather Kiessling reported an open-market sale of 23,124 shares of common stock on April 15, 2026 at a weighted average price of $5.478 per share. The footnotes state this was a "sell to cover" under a Rule 10b5-1 trading plan adopted on December 19, 2025 to cover tax withholding obligations tied to vesting restricted stock awards. After the sale, she directly holds 709,376 shares of ASP Isotopes common stock.
ASP Isotopes Inc. director Duncan Moore reported multiple stock transactions. He sold 11,642 shares of common stock at a weighted average price of $5.205 per share in an open-market trade. Following this sale, he directly owned 1,044,928 shares of ASP Isotopes common stock.
The filing also shows two earlier awards of restricted stock for his service as an independent director: 25,469 shares on November 12, 2025 and 36,548 shares on December 18, 2025, both granted at no cash cost. The sale on April 16, 2026 was executed under a Rule 10b5-1 trading plan adopted on December 31, 2025 and included shares sold to cover income tax liabilities from the vesting of a prior restricted stock award.
ASPI submitted a Form 144 notice regarding the potential sale of 25,469 shares of Common Stock. The shares were acquired as compensation (Restricted Stock Award) on 11/12/2025. The filing is dated 04/16/2026 and lists NASDAQ trading.
ASP Isotopes Inc. reported proposed and recent sales of Common Stock by an affiliate via a Form 144 disclosure. The filing shows a 400,000-share Restricted Stock Award acquired 04/14/2025 and two recent dispositions: 8,438 shares sold on 03/06/2026 for $45,894.28 and 25,000 shares sold on 04/13/2026 for $112,775.00.
The record lists these trades as equity compensation and brokered sales; the filing names Robert Ainscow as the selling contact. Timing and amounts are shown explicitly in the disclosure.